2. Signaling Pathways
  3. Vitamin D Related/Nuclear Receptor
  4. Thyroid Hormone Receptor

Thyroid Hormone Receptor

THR

Thyroid Hormone Receptor

Related Products

PDF 0.46 MB

Thyroid hormone receptor is a member of the nuclear receptor superfamily that shuttles between the cytosol and nucleus. Thyroid hormone receptors are ligand-dependent transcription factors that mediate the biological activities of thyroid hormone (T3). Thyroid hormone receptors are encoded by two genes, one for TRα and another for TRβ, which encode the major isoforms of TR, including TRα1, TRα2, TRβ1, and TRβ2. The thyroid hormone receptors mediate the pleiotropic activities of the thyroid hormone (T3) in growth, development, and differentiation and in maintaining metabolic homeostasis.

Thyroid hormone receptors are zinc finger transcription factors in the erbA superfamily that bind DNA at specific response element sequences (thyroid hormone response elements, TREs) and activate gene expression in response to thyroid hormone (T3). Thyroid hormone receptors have been shown to bind DNA as monomers, homodimers, or heterodimers with another erbA superfamily member, the retinoid X receptor (RXR).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1418A
    DPC-AJ1951 TFA
    		Agonist 99.38%
    DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 TFA in ex vivo and in vivo assays of bone resorption.
    DPC-AJ1951 TFA
  • HY-19513
    MB-07344
    		Agonist 99.86%
    MB-07344 is a potent thyroid hormone receptor (TR)-β agonist with a Ki of 2.17 nM. MB-07344 has additive cholesterol lowering activity in combination with Atorvastatin (HY-B0589) in rabbits, dogs and monkeys.
    MB-07344
  • HY-A0070AG
    Liothyronine (GMP)
    		Agonist
    Liothyronine (Triiodothyronine) (GMP) is the Liothyronine (HY-A0070A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively.
    Liothyronine (GMP)
  • HY-P0002A
    Protirelin acetate
    		Activator 99.87%
    Protirelin Acetate is a highly conserved neuropeptide that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neuromodulatory functions.
    Protirelin acetate
  • HY-P2279
    Parathyroid hormone (1-34) (rat)
    		Agonist 98.59%
    Parathyroid hormone (1-34) (rat) is a parathyroid hormone. Parathyroid hormone (1-34) (rat) improves both cortical and cancellous bone structure. Parathyroid hormone (1-34) (rat) can be used for the research of osteoporosis.
    Parathyroid hormone (1-34) (rat)
  • HY-114806
    Fenclofenac
    		99.09%
    Fenclofenac is an orally active anti-inflammatory agent with a low ulcerogenic effect. Fenclofenac also exhibits antipyretic and analgesic activities, with an oral LD50 of 2280 mg/kg in rats. Fenclofenac can be utilized in inflammation research.
    Fenclofenac
  • HY-160207
    Elunetirom
    		Agonist 99.24%
    Elunetirom (MA-JD21 )is a TR-β selective CNS-penetrant TR-β agonist prodrug and can be used for study of major depressive disorder (MDD).
    Elunetirom
  • HY-10473
    Eprotirome
    		Agonist 99.77%
    Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research.
    Eprotirome
  • HY-14401
    Encaleret
    		99.88%
    Encaleret (CLTX-305) is an orally active antagonist of the calcium-sensing receptor (CaSR), with an IC50 of 12 nM. Encaleret exerts its effect by inhibiting the excessive activity of functional gain-of-function CaSR variants, and can restore blood calcium levels, promote the secretion of parathyroid hormone, improve magnesium and phosphorus metabolism, and increase urinary calcium excretion. Encaleret can be used in the research of diseases such as osteoporosis and autosomal dominant hypocalcemia type 1.
    Encaleret
  • HY-130012
    CO23
    		Agonist 98.00%
    CO23 is a selective thyroid hormone receptor (TR) α agonist and used for growth and development regulation.
    CO23
  • HY-Q04764
    TI17
    		Inhibitor
    TI17 is an inhibitor of the thyroid hormone receptor-interacting protein Trip13 and has anticancer activity. TI17 effectively inhibits multiple myeloma (MM) cell proliferation and induces cell cycle arrest and apoptosis. Trip13 is an AAA-ATPase that mediates double-strand break (DSB) repair; TI17 inhibits Trip13 function and increases DNA damage.
    TI17
  • HY-168046
    ALG-055009
    		Agonist
    ALG-055009 is a selective and orally active Thyroid Hormone Receptor Beta (THR-β) agonist with an EC50 of 0.063 μM. ALG-055009 binds to the T3 hormone pocket of human THR-β, forming polar interactions with protein residues. ALG-055009 can lower total cholesterol levels in rats on a high-fat diet. ALG-055009 exhibits high metabolic stability, good permeability, a long in vivo half-life, and limited drug-drug interaction liability. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease.
    ALG-055009
  • HY-P3960
    (Glu2)-TRH
    		Inhibitor 99.96%
    (Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH; HY-P0002), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS.
    (Glu2)-TRH
  • HY-156679
    VK-0214
    		Antagonist 99.87%
    VK-0214 is an agonist of the thyroid β receptor (TRβ). By activating the expression of ABCD2, it can reduce the accumulation of very long-chain fatty acids (VLCFAs) and further alleviate glioblastoma multiforme. VK-0214 has the effect of regulating fatty acid metabolism and can be used in the research of X-linked adrenoleukodystrophy (X-ALD).
    VK-0214
  • HY-12753A
    Debutyldronedarone hydrochloride
    		Inhibitor 98.32%
    Debutyldronedarone (SR35021) hydrochloride, the main metabolite of Dronedarone, is a selective thyroid hormone receptor α1 (TRα1) inhibitor. Debutyldronedarone hydrochloride inhibits T3 binding to TRα1 and TRβ1 by 77% and 25%, respectively. Debutyldronedarone hydrochloride can be used for the research of arrhythmic.
    Debutyldronedarone hydrochloride
  • HY-127024A
    TR antagonist 2
    		Antagonist
    TR antagonist 2 (Compound 10a) is a competitive thyroid hormone receptors (TRα/β) antagonist (IC50=47 nM). TR antagonist 2 competes with triiodothyronine (T3) for binding to the ligand-binding domain of TR to block receptor-coactivator complex formation and inhibit target gene transcription, reducing thyroid hormone-mediated hypermetabolic effects. TR antagonist 2 is promising for research of hyperthyroidism (e.g., Graves' disease) and thyrotoxicosis.
    TR antagonist 2
  • HY-P4697A
    pTH (44-68) (human) TFA
    		99.45%
    pTH (44-68) (human) TFA is a fragment of human parathyroid hormone (pTH) that lacks the adenylate cyclase-stimulating activity of intact pTH. pTH (44-68) (human) TFA can be used to study the mechanism of action of pTH.
    pTH (44-68) (human) TFA
  • HY-164495
    Sob-AM2
    		Agonist 98.5%
    Sob-AM2 is a potent substrate (Km=1.3 μM) targeting fatty acid amide hydrolase (FAAH) expressed in the brain and has blood-brain barrier permeability. Sob-AM2 delivers high concentrations of Sobetirome (HY-14823) to the central nervous system with minimal peripheral systemic dose, thereby stimulating central thyroid hormone receptor β (TRβ). In addition, Sob-AM2 can prevent myelin and axon degeneration in experimental autoimmune encephalomyelitis (EAE) mice.
    Sob-AM2
  • HY-P10909
    Canvuparatide
    		Agonist
    Canvuparatide (MBX 2109) is a prodrug for parathyroid hormone (PTH) peptide that releases the bioactive PTH[1-32] peptide agonist that retains a fatty acylated lysine (Lys33) at the C-terminus, thereby extending the halflife of Canvuparatide. Canvuparatide can be used for the symptoms of hypoparathyroidism such as hypocalcemia and hyperphosphatemia.
    Canvuparatide
  • HY-P10078
    pTH (39-84) (human)
    		98.88%
    pTH (39-84) (human) is the C-terminal fragment of parathyroid hormone (PTH). pTH (39-84) (human) increases Apoptosis. pTH (39-84) (human) can stimulate osteoclast formation.
    pTH (39-84) (human)
Cat. No. Product Name / Synonyms Application Reactivity